Search in:

Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 3

Submit an article Journal homepage

295

Views

CrossRef citations to date

Altmetric

Reviews

Monoclonal antibody therapies for solid tumors

Dimiter V Tassev Gerstner Sloan-Kettering Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA

Nai-Kong V Cheung Enid A. Haupt Chair in Pediatric Oncology, Gerstner Sloan-Kettering Graduate School of Biomedical Sciences, and Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA +1 646 888 2313; +1 646 422 0452; [email protected]

, MD, PhD

Pages 341-353 | Published online: 08 Apr 2009

Cite this article
https://doi.org/10.1517/14712590802715764

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
PubMed Web of Science ®Google Scholar
Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008;26:1774-7
PubMed Web of Science ®Google Scholar
Crommelin DJA, Sindelar RD. Pharmaceutical Biotechnology. London, Taylor & Francis, Inc.; 2002
Google Scholar
Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008;36:755-68
PubMed Web of Science ®Google Scholar
Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther 2008;8:1151-8
PubMed Web of Science ®Google Scholar
Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-2
PubMed Web of Science ®Google Scholar
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
PubMed Web of Science ®Google Scholar
Giantonio BJ, Catalano PJ, Meropol N, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44
PubMed Web of Science ®Google Scholar
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50
PubMed Web of Science ®Google Scholar
Manegold C. Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008;8:689-99
PubMed Web of Science ®Google Scholar
Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9
PubMed Web of Science ®Google Scholar
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
PubMed Web of Science ®Google Scholar
Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer 2008;7:144-8
PubMed Web of Science ®Google Scholar
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11
PubMed Web of Science ®Google Scholar
Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008;26:3709-14
PubMed Web of Science ®Google Scholar
Buie LW, Valgus J. Bevacizumab: a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 2008;42:1486-90
PubMed Web of Science ®Google Scholar
Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-8
PubMed Web of Science ®Google Scholar
Milano GA, Lescault W, Formento JL, et al. HER2 genetic polymorphism and pharmacodynamics of trastuzumab-based treatment in breast cancer patients. ASCO Annual Meeting Proceedings. J Clin Oncol 2005;23(16S):501
Google Scholar
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48
PubMed Web of Science ®Google Scholar
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
PubMed Web of Science ®Google Scholar
Paik S, Kim C, Jeong J, et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):511
Web of Science ®Google Scholar
Bayo-Calero JL, Mayordomo JI, Sanchez-Rovira P, et al. A Phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 2008;8:264-8
PubMed Web of Science ®Google Scholar
Gallagher DJ, Milowsky MI, Bajorin DF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer 2008;113:1284-93
PubMed Web of Science ®Google Scholar
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78
PubMed Web of Science ®Google Scholar
Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter Phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7
PubMed Web of Science ®Google Scholar
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
PubMed Web of Science ®Google Scholar
Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8
PubMed Web of Science ®Google Scholar
Plate JM. Current immunotherapeutic strategies in pancreatic cancer. Surg Oncol Clin N Am 2007;16:919-43, xi
PubMed Web of Science ®Google Scholar
Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733-9
PubMed Web of Science ®Google Scholar
Butts CA, Bodkin D, Middleman EL, et al. Randomized Phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25:5777-84. Erratum in J Clin Oncol 2008;26(19):3295
PubMed Web of Science ®Google Scholar
Kawaguchi Y, Kono K, Mimura K, et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007;97:494-501
PubMed Web of Science ®Google Scholar
Goncalves A, Esteyries S, Taylor-Smedra B, et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment. BMC Cancer 2008;8:169. Published online June 10 2008, doi:10.1186/1471-2407-8-169
PubMedGoogle Scholar
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
PubMed Web of Science ®Google Scholar
Van Cutsem E, Peeters M, Siena S, et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
PubMed Web of Science ®Google Scholar
Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
PubMed Web of Science ®Google Scholar
Rowinsky EK, Schwartz GH, Gollob JA, et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004;22:3003-15
PubMed Web of Science ®Google Scholar
Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin Cancer Res 2007;13:s4597-601
PubMed Web of Science ®Google Scholar
Carter PJ, Senter PD. Antibody–drug conjugates for cancer therapy. Cancer J 2008;14:154-69
PubMed Web of Science ®Google Scholar
Allen BJ. Clinical trials of targeted alpha therapy for cancer. Rev Recent Clin Trials 2008;3:185-91
PubMedGoogle Scholar
DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med 2005;35:143-51
PubMed Web of Science ®Google Scholar
Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 2008;14:170-7
PubMed Web of Science ®Google Scholar
Jayson GC, Mulatero C, Ranson M, et al. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer. Eur J Cancer 2005;41:555-63
PubMed Web of Science ®Google Scholar
Agus DB, Akita RW, Fox WD, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-37
PubMed Web of Science ®Google Scholar
Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 2006;24:4324-32
PubMed Web of Science ®Google Scholar
Herbst RS, Davies AM, Natale RB, et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007;13:6175-81
PubMed Web of Science ®Google Scholar
Kiewe P, Hasmuller S, Kahlert S, et al. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006;12:3085-91
PubMed Web of Science ®Google Scholar
Kollmannsberger C, Schittenhelm M, Honecker F, et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006;17:1007-13
PubMed Web of Science ®Google Scholar
Graeven U, Kremer B, Sudhoff T, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006;94:1293-9
PubMed Web of Science ®Google Scholar
Seiden MV, Burris HA, Matulonis U, et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007;104:727-31
PubMed Web of Science ®Google Scholar
Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 2008;47:9-19
PubMed Web of Science ®Google Scholar
Modak S, Kramer K, Gultekin SH, et al. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 2001;61:4048-54
PubMed Web of Science ®Google Scholar
Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007;12:864-72
PubMed Web of Science ®Google Scholar
Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann Surg Oncol 2005;12:1005-16
PubMed Web of Science ®Google Scholar
Tarhini AA, Kirkwood JM. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther 2008;8:1583-93
PubMed Web of Science ®Google Scholar
Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [abstract LBA9011]. ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26(suppl)
Google Scholar
Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-94
PubMed Web of Science ®Google Scholar
Hotte SJ, Hirte HW, Chen EX, et al. A Phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3450-5
PubMed Web of Science ®Google Scholar
Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008;61:82-90
PubMed Web of Science ®Google Scholar
Milowsky MI, Nanus DM, Kostakoglu L, et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31
PubMed Web of Science ®Google Scholar
Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-601
PubMed Web of Science ®Google Scholar
Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008;26:2147-54
PubMed Web of Science ®Google Scholar
Rodon J, Patnaik A, Stein M, et al. A Phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. ASCO Meeting Abstracts 2007;25:3590
Google Scholar
Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40
PubMed Web of Science ®Google Scholar
Petrini S, Tessa A, Carrozzo R, et al. Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Abnormal expression in merosin-negative and Duchenne muscular dystrophies. Mol Cell Neurosci 2003;23:219-31
PubMed Web of Science ®Google Scholar
Yeh SD, Larson SM, Burch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med 1991;32:769-76
PubMed Web of Science ®Google Scholar
Saarinen UM, Coccia PF, Gerson SL, et al. Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res 1985;45:5969-75
PubMed Web of Science ®Google Scholar
Chen S, Caragine T, Cheung NK, Tomlinson S. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 2000;60:3013-8
PubMed Web of Science ®Google Scholar
Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood 1992;79:1484-90
PubMed Web of Science ®Google Scholar
Metelitsa LS, Gillies SD, Super M, et al. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcγRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood 2002;99:4166-73
PubMed Web of Science ®Google Scholar
Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/αMβ2-integrin glycoprotein. Crit Rev Immunol 2000;20:197-222
PubMed Web of Science ®Google Scholar
Xu H, Hu J, Cheung NV. Induction of tumor cell death by anti-GD2 monoclonal antibodies (MoAb): Requirement of antibody Fc and a long residence time (slow koff). 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(18S):13507
Google Scholar
Cheung NK, Sowers R, Vickers AJ, et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006;24:2885-90
PubMed Web of Science ®Google Scholar
Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-40
PubMed Web of Science ®Google Scholar
Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998;92:4491-508
PubMed Web of Science ®Google Scholar
Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989;73:1936-41
PubMed Web of Science ®Google Scholar
Cheung NK, Guo HF, Heller G, Cheung IY. Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-GD2 antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 2000;6:2653-60
PubMed Web of Science ®Google Scholar
Kramer K, Cheung NK, Humm J, et al. Pharmacokinetics and acute toxicology of intraventricular 131I-monoclonal antibody targeting disialoganglioside in non-human primates. J Neurooncol 1997;35:101-11
PubMed Web of Science ®Google Scholar
Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007;25:5465-70
PubMed Web of Science ®Google Scholar
Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004;22:3549-57
PubMed Web of Science ®Google Scholar
Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000;18:4077-85
PubMed Web of Science ®Google Scholar
Osenga KL, Hank JA, Albertini MR, et al. A Phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-9
PubMed Web of Science ®Google Scholar
Zalutsky MR, Moseley RP, Coakham HB, et al. Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 1989;49:2807-13
PubMed Web of Science ®Google Scholar
Brown MT, Coleman RE, Friedman AH, et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results. Clin Cancer Res 1996;2:963-72
PubMed Web of Science ®Google Scholar
Reardon DA, Akabani G, Coleman RE, et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J Clin Oncol 2006;24:115-22
PubMed Web of Science ®Google Scholar
Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97
PubMed Web of Science ®Google Scholar
Reardon DA, Zalutsky MR, Akabani G, et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008;10:182-9
PubMed Web of Science ®Google Scholar
Reardon DA, Quinn JA, Akabani G, et al. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med 2006;47:912-8
PubMed Web of Science ®Google Scholar
Zalutsky MR, Reardon DA, Akabani G, et al. Clinical experience with α-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49:30-8
PubMed Web of Science ®Google Scholar
Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005;4:1318-24
PubMed Web of Science ®Google Scholar
Raja C, Graham P, Abbas Rizvi SM, et al. Interim analysis of toxicity and response in Phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007;6:846-52
PubMed Web of Science ®Google Scholar
Fridman WH. Fc receptors and immunoglobulin binding factors. Faseb J 1991;5:2684-90
PubMed Web of Science ®Google Scholar
Kratz F, Muller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem 2008;3:20-53
PubMed Web of Science ®Google Scholar
Magdelaine-Beuzelin C, Kaas Q, Wehbi V, et al. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007;64:210-25
PubMed Web of Science ®Google Scholar
Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8
PubMed Web of Science ®Google Scholar
Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13
PubMed Web of Science ®Google Scholar
Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007;25:5410-7
PubMed Web of Science ®Google Scholar
Allen BJ, Raja C, Rizvi S, et al. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys Med Biol 2007;52:L15-9
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Monoclonal antibody therapies for solid tumors

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Monoclonal antibody therapies for solid tumors

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date